



About us


Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,790 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 322,253 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company provides related medical services in the field of Care Coordination.

Key figures – 1st quarter 2018

		Q1 2018	Growth cc
Revenue	€	3,976 M	(1%)
Operating income (EBIT)	€	497 M	(15%)
Net income ¹	€	279 M	0%
Basic earnings per share	€	0.91	0%
Net cash provided by (used in) operating activities	€	(45) M	
Free cash flow	€	(263) M	
Free cash flow after investing activities	€	(444) M	
Employees		114,831	

¹ attributable to shareholders of Fresenius Medical Care AG & Co. KGaA


Q1 2018: Revenue per region (in € million)




Q1 2018: Patients, treatments, clinics

	Patients	Treatments (in M)	Clinics
North America	197,339	7.5	2,419
EMEA	63,114	2.4	754
Asia-Pacific	30,194	1.1	385
Latin America	31,606	1.2	232
Total	322,253	12.2	3,790

Basic earnings & dividend per share



Balance sheet (in € billion)



Strategy

Our strategy in the coming years will pursue the following four strategic objectives:

- Growing continuously and expanding our global presence
- Tapping into new business areas
- Enhancing products and treatments
- Expanding operational excellence and flexibility

Goals for 2018

Revenue growth	5 to 7% at cc
Net income growth	13 to 15% at cc



History

- September 30, 1996: Foundation of the company
- October 1, 1996: First listing of the shares on the Frankfurt Stock Exchange
- October 2, 1996: First listing of the shares on the New York Stock Exchange
- As of September 20, 1999: Inclusion in the DAX (Deutscher Aktienindex)

Share price - last 12 months (in €)



Basic share data


Ticker Symbols:

Frankfurt Stock Exchange	FME
New York Stock Exchange (NYSE)	FMS
Reuters: XETRA / ADR NYSE:	FMEG.DE/FMS.N
Bloomberg: XETRA / ADR NYSE:	FME GY / FMS US

Security Identification numbers:

WKN	578 580
ISIN	DE 0005785802
CUSIP No. (NYSE)	358029106

Geographical distribution of identified shares



Share capital (as of end of April 2018)

Number of shares outstanding	308.121.322
<i>Fresenius SE & Co. KGaA</i>	30.6%
Free float	~69%
Market capitalization	~26 BN €

Ratings

Standard & Poor's	BBB- / positive outlook
Moody's	Baa3 / stable outlook
Fitch	BBB- / stable outlook

Management Board

- Rice Powell (Chairman)
- Michael Brosnan (Finance)
- Bill Valle (North America)
- Dr. Olaf Schermeier (Research & Development)
- Kent Wanzek (Production)
- Harry de Wit (Asia-Pacific)
- Katarzyna Mazur-Hofsäss (EMEA)

Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Rolf A. Classon
- William P. Johnston
- Deborah Doyle McWhinney
- Pascale Witz

Financial calendar

Annual General Meeting:	May 17, 2018
Report on the 2nd quarter 2018:	July 31, 2018
Report on the 3rd quarter 2018:	October 30, 2018

Please note that these dates might be subject to changes.

Contacts

Fresenius Medical Care AG & Co. KGaA
Investor Relations & Corporate Communications
Else-Kröner-Str. 1, 61352 Bad Homburg
Email: ir@fmc-ag.com

Dr. Dominik Heger

SVP & Head of IR & Corp. Communications
P: +49(0)6172-609-2525 F: +49(0)6172-609-2301